Cannabis Chart Of The Week: The Market Reacted Rationally (For A Change) To 4th Qtr 2023 Earnings Releases
Portfolio Pulse from Viridian Capital Advisors
The 4th quarter 2023 earnings for the cannabis sector showed a positive trend with a significant correlation between EBITDA surprises and stock performance. Green Thumb and Trulieve reported notable EBITDA beats, while Marimed, Cannabist, and TerrAscend faced significant misses. Analysts have adjusted their 2024 EBITDA estimates slightly downwards, reflecting modest expectations for revenue growth and margin expansion. The Viridian Cannabis Deal Tracker highlights the importance of these trends for investors.
March 18, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cannabist's EBITDA miss by 38% and stock decline of nearly 21% indicate a negative short-term outlook for its stock.
Cannabist's significant EBITDA miss and subsequent stock decline reflect major operational and market challenges, likely leading to continued investor caution.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Marimed missed EBITDA estimates by 25% due to supply chain issues, likely leading to a negative short-term impact on its stock.
Marimed's significant EBITDA miss, caused by supply chain disruptions, could dampen investor sentiment and negatively affect its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
TerrAscend's 17.6% EBITDA miss, mainly due to cultivation issues, suggests a negative short-term impact on its stock.
TerrAscend's EBITDA miss, attributed to cultivation problems, could erode investor confidence and negatively impact its stock price in the near term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Green Thumb beat EBITDA estimates by 14%, showing strength in Maryland. This positive performance could lead to a short-term uptick in its stock price.
The significant beat in EBITDA estimates by Green Thumb, driven by its performance in Maryland, indicates strong operational efficiency and market presence, likely leading to investor optimism.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Trulieve's EBITDA beat by 22.3% due to cost control and margin improvements, suggesting a potential positive short-term impact on its stock.
Trulieve's substantial EBITDA beat, attributed to effective cost management and margin improvements, presents a strong case for investor confidence and potential stock appreciation.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90